Thursday, 7 June 2018

33. Childhood Leukaemia Targeted Therapy Trialsdrug trial success


Photo: Rosewell Park Cancer Center, Buffalo, NY.
Stage 3 trials of an experimental targeted cancer drug produced by AstraZeneca that includes a bacterial toxin shows promise in treating the most common cancer in children, B-cell acute lymphoblastic leukaemia (ALL). However, therapeutic benefits in the trial appear to be limited, because trial patients are quickly developing therapeutic resistance to the drug and relapse.
A US trial however has shown that resistance to the targeted toxin-based therapy can possibly be overcome by combining it with another leukaemia drug, (Moxe), thus increasing its efficacy in patients with relapsed and chemotherapy-resistant (refractory) ALL.
Elsewhere Pilot phase 2 trials involving 154 children’s hospitals across USA are underway to test combination treatment for ALL, its infant tolerability and long-term event-free infant survival. The trials use a cocktail of targeted chemotherapy drugs that work in three different ways to stop cancer cell growth; by killing the cells, by stopping them from dividing, or by stopping them from spreading.
There is still a long way to go before the long-term efficacy of targeted drug combinations are proven, accepted and licensed by the FDA in USA and the NHS in UK for treating infant leukaemia.  Research clinicians however are showing significant progress in harnessing the body’s own defence system by using modified T-cell based therapy to attack and kill cancer cells in both ALL and other cancers; a radically different approach to previous conventional chemotherapy treatments.
Genetically modified so-called chimeric antigen receptor (CAR) T-cells are showing remarkable efficacy for the treatment of chemotherapy resistant relapsed B-cell ALL, and other cancers, although tumour cells still adapt to evade even this new type of treatment.  It is hoped that selecting the right combination of therapies will limit the ability of cancer cells to escape such combinatorial approaches to treatment.
Filed March, 2018, Caring Cancer Trust.

32. NHS RAPID pathway to prostate cancer diagnosis



A new pilot high-speed path to treatment for prostate cancer that can significantly cut diagnosis time was presented at the European Association of Urology Conference in Copenhagen in March by Professor Hashim Ahmed, Chair of Urology at Imperial College London.
The procedure can cut waiting time for detection in the UK from an average 56 days to 17 days after referral from GP. As the difference between early and late detection of the disease is a matter of life and death, this new rapid procedure could save many lives if rolled out by the NHS across the country in the 2020s, following clinical trials.
The new world-leading (magnetic resonance imaging (MRI) procedure, is completed in one day rather than several. It was successfully piloted at London’s Imperial College Charing Cross Hospital and Epsom Hospital in 2017. Some 4 in 10 patients are cleared immediately after their MRI scan and the rest have a precision biopsy using fusion technology later that same day.
Professor Hashim Ahmed to led the treatment trial said: “The NHS has led the research that underpins this RAPID pathway to improve the diagnosis of prostate cancer. The NHS is now leading the way in ensuring all men get to benefit from this innovation. Fast access to high quality prostate MRI allows many men to avoid invasive biopsies as well as allowing precision biopsy in those men requiring it to find high risk tumours much earlier.” access to high quality prostate MRI allows many men to avoid invasive biopsies as well as allowing precision biopsy in those men requiring it to find high risk tumour much earlier,”
Prostate cancer is now the second biggest killer for men after lung cancer. It kills over 10,000 men in UK, 28,000 in USA and 4,000 in Canada each year.

Filed 22 March 2018 Caring Cancer Trust

Monday, 1 January 2018

31. Breast Cancer Diagnosis Breakthrough

     



         Recent research led by University College London has identified a cancer signature in DNA changes apparent in blood tests. These signal a possibly fatal breast cancer symptom up to one year earlier than current medical diagnosis techniques which may still test negative in current breast screening.

     “This may enable individualised treatment, which could even begin in the absence of radiological evidence in the breast,’ UCL’s Professor Martin Widschwendler, who co-authored the study, has stated.
     Such early detection and consequent early hormone treatment could mean a difference between life and death. It would also eliminate the possibility of over-diagnosis and subsequent debilitating treatment of slow growing but benign tumours that are frequently detected in mammography screening.  
     Further study and trials are necessary before this early detection process can be made available on the NHS or in USA.
     Latest statistics show that 1 in 8 women in UK and USA will be diagnosed with breast cancer at sometime in their lifetime. Breast and lung cancers are, in fact, the foremost cause of female cancer death in these countries.
     The incidence of breast and lung cancer is in fact increasing, thanks to the growth and ageing of the population, together with an increasing prevalence of risk factors associated with economic growth and urbanisation, such as smoking, obesity, diet, and physical inactivity.
     As with all cancers, the risk of developing breast, (or other), cancer depends on a number of factors that are possibly outside your immediate control.  
     You can however eliminate the breast cancer risk by cutting alcohol out altogether, or at least down to the national guidelines, to ensure that you are not one of the 12,000 new cases of cancer in UK each year caused by alcohol, which include cancers of the mouth, throat, larynx, oesophagus, breast, live and bowel.
     Post-menopausal women who are overweight or obese are also at increased breast cancer risk.  Since both alcohol and obesity significantly increase the risk factor for a large number of cancers for both sexes at any age, you can do yourself a big favour if you over-indulge on the booze and/or are overweight by changing your lifestyle.
1.    Cut down on the booze!
2.  Change your diet to lose weight!
     3.  Get out and stretch those legs! 

Ian MacWatt
Further Reading

     Methylation patterns in serum DNA for early identification of disseminated breast cancer. Report on the UCL Study.
     Lung cancer and breast cancer; the leading cause of female cancer death in developed countries.                                                                                        
     Cancer Prevention
     Obesity and Cancer
     Alcohol and Health.
Nature
     Alcohol damages DNA and increases cancer risk


Filed March 2018 Caring Cancer Trust